For the moments that should

take your
breath away

For the moments that should

make your
heart fill

For the moments that should

bring your hand
to your chest

driven by the heart

To change the world for people with serious cardiovascular diseases through bold and innovative science, we’re pioneering a precision medicine approach to treating cardiomyopathies and other forms of heart failure that results from biomechanical defects in cardiac muscle contraction.

Our Programs

Mavacamten

Obstructive HCM

Phase 3

Non-obstructive HCM

Phase 2

Mavacamten

Mavacamten is designed to address the excessive contractility, left ventricular hypertrophy and reduced compliance characteristic of hypertrophic cardiomyopathy (HCM).

MYK-491

Precision Systolic Disease Indications

Phase 2

MYK-491

MYK-491 is designed to increase contractility without impairing diastolic filling in patients with systolic heart failure.

MYK-224

HCM

Phase 1

MYK-224

MYK-224 is our second program targeting hypercontractility and impaired relaxation.

ACT-1

Precision Systolic Disease Indications

Preclinical

ACT-1

ACT-1 is our preclinical activator program directed toward increasing cardiac contractility in targeted dilated cardiomyopathy (DCM).

LUS-1

Precision Diastolic Disease Indications

Preclinical

LUS-1

LUS-1 is an emerging preclinical program targeting a muscle abnormality that results in impaired relaxation of the left ventricle.

We're all in because we all have a heart

scientific app r oach OUR FOR researchers patients FOR

news releases

see all news

we're hiring

Research Associate I, Biology

Research

Senior Statistical Scientist, Biostatistics

Clinical Development

Manager, Medical Communications

Medical Affairs

see all openings

what's happening

HFSA 2019

Sep 15, 2019

Flexing our heart muscle (expertise)

Sep 12, 2019

MyoKardia knows: My Heart Counts

Sep 08, 2019

Life at MyoKardia